Breakthrough Vaccine to Potentially Protect Against the Spread of COVID-19

At Pfizer, we are working at an unprecedented speed to develop, test and manufacture an mRNA-based vaccine to prevent COVID-19.

Manufacturing Capabilities

We operate one of the most sophisticated supply chain systems in the industry, with more than 40 Pfizer-owned sites and more than 200 suppliers globally.

Globally, we have more than:

- 28,000 colleagues
- Supplying vaccines to 165 countries
- Producing more than 23 billion doses of medications per year, including >200 million vaccine doses and 1.5 billion sterile units

For biologics, vaccines & sterile injectables, we have:

- 17,000 colleagues in 23 manufacturing facilities in 11 countries
- Capacity to manufacture more than 500 million doses of medicines and vaccines
Scaling for Success

mRNA is a new mechanism for vaccine creation that requires rapid development and scale-up of novel manufacturing technologies. Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

Pfizer has manufacturing and distribution sites across the U.S. Initially for the COVID-19 vaccine program, we are leveraging three of them:

How It Happens

Pfizer’s manufacturing and supply chain professionals have been taking several steps to accelerate the scale-up and manufacture four of the most promising vaccine leads:

- Exchanging technology to enable rapid facility, equipment and process design planning
- Ordering materials and starting to manufacture potential vaccine candidates
- Putting two parallel supply chains in place for appropriate redundancies
- Modifying facilities for the vaccine candidates and re-prioritizing capacity
- Hiring and training staff to give our operations even more support and flexibility
- Investing at risk so we can quickly produce as many doses of a potential vaccine as possible

NOVEMBER 2020